-
Goodbye BMI? Why Body Composition Is Gaining Ground in Clinics
The rise of incretin-based therapies for obesity care, like Wegovy (semaglutide) and Zepbound (tirzepatide), has brought renewed attention to the risk of muscle atrophy that can accompany rapid weight loss. To better assess…
-
GLP-1 Success Starts with Dietitian Leadership
It should come as no surprise that a large part of the success with incretin-based therapies— like Ozempic, Wegovy, Mounjaro, and Zepbound—stems from the effective integration of lifestyle modifications, particularly nutrition. This success…
-
GLP-1 Therapy Part 2: Preventing and Managing Side Effects
I recently had the pleasure of presenting at the Colorado Academy of Nutrition and Dietetics Annual Conference on the topic of nutrition strategies for effective GLP-1 use in obesity treatment. This premier event,…
-
GLP-1 Therapy Part 1: Setting Realistic Weight Loss Expectations
I recently had the pleasure of speaking at the Colorado Academy of Nutrition and Dietetics Annual Conference on the topic of nutrition strategies for effective GLP-1 use in obesity treatment. This premier event,…
-
Mitigating Therapeutic Inertia of GLP-1 Use in T2D
Glucagon-like peptide-1 receptor agonists, commonly known as GLP-1 RAs, have recently garnered significant media attention. Initially developed to improve glycemic control in patients with type 2 diabetes, these medications have also proven to…
Diabetes Care and Education
